Sotio Biotech Inc.
Records under this name other than the patents Sotio Biotech Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| 17/257,469 | Chimeric Receptors in Combination with Trans Metabolism Molecules Enhancing Glucose Import and Therapeutic Uses Thereof Abandoned Abandoned Jan 15, 2025 | Abandoned | Abandoned Jan 15, 2025 | |
| 17/274,021 | Chimeric Receptor Polypeptides in Combination with Trans Metabolism Molecules Modulating Intracellular Lactate Concentrations and Therapeutic Uses Thereof Abandoned Abandoned Sep 4, 2024 | Abandoned | Abandoned Sep 4, 2024 | |
| 17/291,963 | ANTI-GPC3 Chimeric Antigen Receptors (CARs) in Combination with Trans Co-Stimulatory Molecules and Therapeutic Uses Thereof Abandoned Abandoned Dec 19, 2024 | Abandoned | Abandoned Dec 19, 2024 | |
| 17/788,226 | Tumor-Specific Claudin 18.2 Antibodies held by Sotio Biotech A.S. Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/573,387 | Interleukin 15 Variants held by Cytune Pharma Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/573,397 | INTERLEUKIN-15 Based Immunocytokines held by Cytune Pharma Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/695,383 | Chimeric Receptor Polypeptides in Combination with Trans Metabolism Molecules That Re-Direct Glucose Metabolites Out of the Glycolysis Pathway and Therapeutic Uses Thereof Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/709,546 | Treatment of Myxoid/Round Cell Liposarcoma Patients Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/784,028 | Chimeric Antigen Receptor Polypeptides in Combination with Trans Metabolism Molecules Modulating Krebs Cycle and Therapeutic Uses Thereof Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 19/104,547 | Genetically Engineered Immune Cells with Chimeric Receptor Polypeptides in Combination with Multiple Trans Metabolism Molecules and Therapeutic Uses Thereof Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. |